An innovation-driven, global pharmaceutical company, Zydus Cadila revealed that its plasmid DNA vaccine candidate named ZyCoV-D for COVID-19 completed the preclinical trials. ZyCoV-D vaccine candidate was found to be safe, well-tolerated, and immunogenic in the preclinical toxicity studies.
Notably, the Company has received permission from the DCGI (Drug Controller General of India) CDSCO to commence Phase 1/2 human clinical trials in India.
Moreover, Zydus intends to commence the human clinical trials in July-2020.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.